| Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More | Frank Vinluan | 09/18/20 | National |
| Moderna CMO Talks COVID-19 Vaccine at Xcelerate Next Week | Editors | 09/16/20 | Boston |
| Neogene Therapeutics Grabs $110M to Tackle Solid Tumors With Cell Therapy | Frank Vinluan | 09/15/20 | Europe |
| Seattle Genetics Lands $1.72B From Merck in Pair of Cancer Drug Deals | Frank Vinluan | 09/14/20 | Seattle |
| Xconomy Awards On-Demand ‘Meet the Finalists’ Webcast Series Continues This Week | Editors | 09/14/20 | Boston |
| Gilead Adds “Cornerstone” Cancer Drug in $21B Immunomedics Buyout | Frank Vinluan | 09/14/20 | San Francisco |
| Join Xconomy Next Week at the Virtual Xcelerate Keynote Series at Biotech Week Boston | Editors | 09/14/20 | Boston |
| Bio Roundup: COVID-19 Pact, Gavreto Approval, Generative Biology & More | Frank Vinluan | 09/11/20 | National |
| Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More | Frank Vinluan | 09/04/20 | National |
| Reeling From FDA Rejection, Intercept Pharma Slashes Headcount by 25% | Frank Vinluan | 09/01/20 | New York |
| Early Bird Sale for Xcelerate at Biotech Week Boston Ends This Friday | Editors | 08/31/20 | Boston |
| Biotech Roundup: FDA Culpa, Tricida Trips, Freenome’s Funding & More | Frank Vinluan | 08/28/20 | National |
| Athira Aims for the Nasdaq to Advance Alzheimer’s Drug to Phase 2 Tests | Frank Vinluan | 08/27/20 | Seattle |
| AbbVie & UroGen Overactive Bladder Treatment Misses in Phase 2 Trial | Sarah de Crescenzo | 08/27/20 | New York |
| Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases | Frank Vinluan | 08/26/20 | Boston |
| FDA Adds Plasma as 2nd COVID-19 Treatment Under Emergency Guidelines | Sarah de Crescenzo | 08/24/20 | National |
| Bio Roundup: J&J Buyout, BioMarin Rebuffed, Poseida on Hold & More | Sarah de Crescenzo | 08/21/20 | National |
| J&J Boosts Autoimmune Disease Drug Pipeline With $6.5B Momenta Buyout | Frank Vinluan | 08/19/20 | New York |
| Bristol Myers Squibb to Splash Out $475M on Dragonfly Immunotherapy | Sarah de Crescenzo | 08/17/20 | New York |
| Advisory Body Backs MesoBlast Therapy for Transplant Complication | Sarah de Crescenzo | 08/14/20 | New York |
| CureVac’s IPO Hauls In $213M as Key mRNA COVID-19 Vaccine Test Nears | Frank Vinluan | 08/14/20 | Europe |
| Bio Roundup: Seres Soars, MesoBlast Vote, Duchenne Decision & More | Frank Vinluan | 08/14/20 | National |
| With FDA Nod, NS Pharma Duchenne Drug Becomes Sarepta Competitor | Frank Vinluan | 08/12/20 | New York |
| Perceptive Advisors’ LianBio Inks Deals With BridgeBio, MyoKardia | Sarah de Crescenzo | 08/12/20 | San Francisco |
| F2G Lands $60M for a New Tack on Taking Out Rare Fungal Infections | Frank Vinluan | 08/12/20 | Europe |
| Pfizer’s Bourla: There’s Coronavirus Vaccine Pressure, But It’s Not Political | Derrick Gingery | 08/12/20 | National |
| Bayer Boosts Women’s Health Drug Pipeline, Paying $425M for KaNDy | Frank Vinluan | 08/11/20 | Europe |
| Bio Roundup: A Telehealth Combo, FDA’s BCMA OK, Biogen’s Bet & More | Sarah de Crescenzo | 08/07/20 | National |
| As Patients Pivot to Telehealth, Teladoc & Livongo Plan $18.5B Tie-Up | Frank Vinluan | 08/05/20 | New York |
| Still Stuck on Adhesion Issues, FDA Rejects DBV’s Peanut Allergy Patch | Sarah de Crescenzo | 08/04/20 | National |
